Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below

      Duodopa Logo
      new loz 1
      new loz 2
      new loz 1 mobile
      new loz 3 mobile
      Duodopa Header

      DUODOPA (levodopa/carbidopa intestinal gel) is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.1

      Levodopa may activate malignant melanoma, so DUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.1

      Some patients may not be suitable for DUODOPA. You are strongly advised to read the Prescribing Information (PI) and Summary of Product Characteristics (SmPC), accessible via the links above, to evaluate patient suitability.

      This page is intended for UK Healthcare Professionals experienced in the diagnosis and management of Parkinson's disease only, with patients who have already been prescribed DUODOPA (levodopa/carbidopa intestinal gel)

      Patient Support Programme (PSP)

      The PSP is a package deal developed and funded by AbbVie. Patients receiving Duodopa have access to a patient support service, provided free of charge to the NHS.

       

      The service provides a team of Parkinson’s specialist nurses who deliver 1:1 care and support in hospitals and homes across the country.

      This includes pre-assessment visits, support during NJ/PEG-J placement, 1:1 in-hospital titration guidance, follow-up home visits and ongoing support.

      Duodopa nurses are available to support and educate the patient through every stage of the Duodopa treatment pathway.

       

      Below is an introduction to the two AbbVie service partners who provide patient support as part of the PSP.

      NJ=nasojejunal; PEG-J=percutaneous endoscopic gastro-jejunostomy.

      This page is intended for UK Healthcare Professionals experienced in the diagnosis and management of Parkinson's disease only, with patients who have already been prescribed DUODOPA (levodopa/carbidopa intestinal gel)

      Resources
      DUODOPA PRESCRIBING INFORMATION

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.

      Adverse events should also be reported to AbbVie on [email protected]

       

      UK-DUOD-230106. Date of preparation: December 2023.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected]

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.